z-logo
Premium
Immunological studies on mouse mammary tumors. I. Induction of resistance to tumor isograft in C3H/He mice
Author(s) -
Nishioka Kusuya,
Irie Reiko Furuse,
Inoue Masaharu,
Chang Shaoyuan,
Takeuchi Shoshichi
Publication year - 1969
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910040202
Subject(s) - isograft , spleen , ratón , mammary tumor , intraperitoneal injection , inoculation , medicine , biology , pathology , andrology , immunology , transplantation , endocrinology , cancer , breast cancer
An isografted tumor MM2, originating from a spontaneous mammary tumor in a C3H/He/mouse, killed 4‐ to 5‐week‐old mice within 30 days through intraperitoneal injection of 2 × 10 4 cells per mouse. It was shown that resistance to the isograft was induced by injection of 1.5 × 10 5 or 2.0 × 10 5 tumor cells sensitized with serum (5 μg antibody N) of rabbits immunized with the tumor. Four weeks after injection of the sensitized MM2 cells, 173 C3H/He mice were challenged intraperitoneally with fresh unsensitized MM2 in doses of 5 × 10 5 to 1 × 10 6 cells per mouse. Of these, 119 mice survived without any sign of tumor growth while all untreated mice died. The mean survival time for untreated mice was 18.1 days (± 1.7) when inoculated with 5 × 10 5 cells and 16.2 days (± 1.8) when inoculated with 1 × 10 6 cells. After the second challenge with the same number of fresh unsensitized cells, 117 out of 119 mice survived without any sign of tumor growth. All of 15 mice randomly selected from these resistant mice were tested for acceptance of skin grafts from normal C3H/He mice. The grafts showed no rejection even 150 days after the second graft. After hyperimmunization of these resistant mice, the serum of the spleen extract taken from the mice inhibited growth of tumors when the tumors were premixed in vitro and injected intraperitoneally into C3H/He mice.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here